Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nelida Garretto is active.

Publication


Featured researches published by Nelida Garretto.


Neurology | 2000

Spontaneous and reflex movements in brain death

Gustavo Saposnik; José A. Bueri; Jorge Maurino; R. Saizar; Nelida Garretto

Article abstract Spontaneous and reflex movements may be found in patients with brain death (BD). The authors prospectively evaluated their frequency using a standardized protocol. Among 38 patients who fulfilled criteria for BD, the authors found 15 (39%) with spontaneous or reflex movements. The most common movement was finger jerks. Undulating toe flexion sign, triple flexion response, Lazarus sign, pronation–extension reflex, and facial myokymia also were seen. These movements may be more common than reported and do not preclude the diagnosis of BD.


European Journal of Neurology | 2015

Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale.

Pablo Martinez-Martin; Kallol Ray Chaudhuri; Jose Manuel Rojo-Abuin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M. Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry Moore; Mayela Rodríguez-Violante; Carlos Singer; Barbara C. Tilley; Jing Huang; Glenn T. Stebbins; Christopher G. Goetz

Although Parkinsons disease (PD) is characterized by typical motor manifestations, non‐motor symptoms (NMS) are an outstanding part of the disease. At present, several specific instruments for assessment of NMS are available. The objective of our study was to determine the performance of the Movement Disorder Society‐Unified Parkinsons Disease Rating Scale (MDS‐UPDRS): Part I – Non‐Motor Aspects of Experiences of Daily Living (nM‐EDL) compared with the Non‐Motor Symptoms Scale (NMSS).


European Journal of Neurology | 2014

Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.

Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Maria João Forjaz; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M. Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry Moore; Mayela Rodríguez-Violante; Carlos Singer; Barbara C. Tilley; Jing Huang; Glenn T. Stebbins; Christopher G. Goetz

The Movement Disorder Society sponsored version of the Unified Parkinsons Disease Rating Scale (MDS‐UPDRS) is a comprehensive instrument for assessing Parkinsons disease (PD). The present study was aimed at determining the relationships between MDS‐UPDRS components and health‐related quality of life (HRQoL) evaluations in PD patients.


Movement Disorders | 2004

Improvement of blepharospasm with Zolpidem

Nelida Garretto; José A. Bueri; R. Rey; Tomoko Arakaki; Gabriela Ñano; Marcela Mancuso

Zolpidem (ZLP) is an imidazopyridine that binds to GABA receptors. We report on improvement of blepharospasm in 3 patients treated with ZLP. The GABAergic action of this drug on the output structures of the basal ganglia could explain the improvement of blepharospasm in these patients.


Parkinsonism & Related Disorders | 2016

Satisfaction with life scale (SLS-6): first validation study in Parkinson's disease population

Leire Ambrosio; Mari Carmen Portillo; Carmen Rodriguez-Blazquez; Juan Carlos Martinez-Castrillo; Mayela Rodríguez-Violante; Marcos Serrano-Dueñas; Víctor Campos-Arillo; Nelida Garretto; Tomoko Arakaki; Mario Alvarez; Ivonne Pedroso-Ibáñez; Ana Carvajal; Pablo Martínez-Martín

INTRODUCTION To explore the psychometric attributes of a new Satisfaction with Life Scale (SLS-6) in a wide Spanish-speaking population with Parkinsons disease (PD). METHODS This was an international, cross-sectional study. Several rater-based and patient-reported outcomes measures for evaluation of PD (e.g., Scales for Outcomes in Parkinsons Disease-Motor) and other constructs (e.g., Duke-UNC Functional Social Support Questionnaire, Scale for Living with Chronic Illness) were applied together with the SLS-6. Acceptability, scaling assumptions, reliability, precision, and construct validity were tested. RESULTS The study included 324 patients from five countries, with age (mean ± standard deviation) 66.67 ± 10.68 years. None of the SLS-6 items had missing values and all acceptability parameters fulfilled the standard criteria. Scaling assumptions allowed the calculation of a summary index from items 2 to 6, complementary to the global evaluation (item 1). For these five items, Cronbachs alpha was 0.85; the corrected item-total correlation 0.53-0.73; inter-item correlation, 0.45-0.70, with an item homogeneity index of 0.55. The standard error of measurement, based on Cronbachs alpha for a single observation, was 3.48. SLS-6 correlations were moderate to strong (rs ≥ 0.35) with the patient-reported outcomes and weak to moderate with the rater-based assessments used in the study. The SLS-6 total score was significantly different according to PD severity levels established according to Hoehn and Yahr staging, Clinical Impression of Severity Index, and Patient-Based Global Impression of Severity scale. CONCLUSION The results suggest that SLS-6 is an easy, feasible, acceptable, consistent, precise and valid measure to evaluate satisfaction with life in PD patients.


Arquivos De Neuro-psiquiatria | 2013

Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica

Luz Abaroa; Sergio Alejandro Rodríguez-Quiroga; Luciana Melamud; Tomoko Arakaki; Nelida Garretto; Andres Villa

UNLABELLED Tonic spasms have been most commonly associated with multiple sclerosis. To date, few reports of series of patients with neuromyelitis optica and tonic spasms have been published. METHODS We analyzed the characteristics and frequency of tonic spasms in 19 subjects with neuromyelitis optica. Data was collected using a semi-structured questionnaire for tonic spasms, by both retrospectively reviewing medical records and performing clinical assessment. RESULTS All patients except one developed this symptom. The main triggering factors were sudden movements and emotional factors. Spasms were commonly associated to sensory disturbances and worsened during the acute phases of the disease. Carbamazepine was most commonly used to treat the symptom and patients showed good response to the drug. CONCLUSIONS Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica.


npj Parkinson's disease | 2016

Analysis of four scales for global severity evaluation in Parkinson’s disease

Pablo Martinez-Martin; Jose Manuel Rojo-Abuin; Mayela Rodríguez-Violante; Marcos Serrano-Dueñas; Nelida Garretto; Juan Carlos Martínez-Castrillo; Víctor Campos Arillo; William Fernández; Pedro Chaná-Cuevas; Tomoko Arakaki; Mario Alvarez; Ivonne Pedroso Ibáñez; Carmen Rodriguez-Blazquez; Kallol Ray Chaudhuri; Marcelo Merello

Global evaluations of Parkinson’s disease (PD) severity are available, but their concordance and accuracy have not been previously tested. The present international, cross-sectional study was aimed at determining the agreement level among four global scales for PD (Hoehn and Yahr, HY; Clinical Global Impression of Severity, CGIS; Clinical Impression of Severity Index, CISI-PD; and Patient Global Impression of Severity, PGIS) and identifying which of them better correlates with itemized PD assessments. Assessments included additional scales for evaluation of the movement impairment, disability, affective disorders, and quality of life. Spearman correlation coefficients, weighted and generalized kappa, and Kendall’s concordance coefficient were used. Four hundred thirty three PD patients, 66% in HY stages 2 or 3, mean disease duration 8.8 years, were analyzed. Correlation between the global scales ranged from 0.60 (HY with PGIS) to 0.91 (CGIS with CISI-PD). Kendall’s coefficient of concordance resulted 0.76 (P<0.0001). HY and CISI-PD showed the highest association with age, disease duration, and levodopa-equivalent daily dose, and CISI-PD with measures of PD manifestations, disability, and quality of life. PGIS and CISI-PD correlated similarly with anxiety and depression scores. The lowest agreement in classifying patients as mild, moderate, or severe was observed between PGIS and HY or CISI-PD (58%) and the highest between CGIS and CISI-PD (84.3%). The four PD global severity scales agree moderately to strongly among them; clinician-based ratings estimate PD severity, as established by other measures, better than PGIS; and the CISI-PD showed the highest association with measures of impairment, disability, and quality of life.


Arquivos De Neuro-psiquiatria | 1995

Hemicorea asociada a toxoplasmosis cerebral y SIDA

Nelida Garretto; J.A. Bueri; M. Kremenchutzky; D. Consalvo; M. Segura; Osvaldo Genovese

Only 12 AIDS cases with hemichorea were reported in the literature. We report the first case of hemichorea associated with AIDS and cerebral toxoplasmosis in our country. A 26-year-old man had 3 episodes of focal seizures on the left side with subsequent loss of consciousness. A few weeks later, he noticed progressive left-sided weakness. Examination revealed a left hemiparesis. MRI of the head showed a round mass in the right frontal lobe and a smaller lesion in the left temporo-occipital area. Laboratory showed positive serum ELISA and Western Blot analysis for HIV antibodies. Serum tests for Toxoplasma showed elevated titers. He was treated with pyrimethamine and sulfadiazine. His weakness improved and he had no further seizures. Two weeks later, choreic movements appeared in the left foot, finally involving the entire left hemibody. A second MRI showed a new small lesion in the right cerebral peduncle. The patient completed 6 weeks of treatment, with further reduction in the size of the lesions. Nevertheless, the left hemichorea persisted. We believe that the hemichorea our patient had was caused by the contralateral peduncular lesion. Lesions involving the subthalamic nucleus or its connections may cause contralateral hemiballismus or hemichorea. In spite of the favorable response to antitoxoplasmic therapy, the hemichorea persisted. The present report illustrates an uncommon neurological complication in AIDS. We believe that a combination of a focal cerebral lesion and the HIV infection caused the movement disorder presented by the patient.


Movement Disorders Clinical Practice | 2017

Differences in MDS‐UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration

Matej Skorvanek; Pablo Martinez-Martin; Norbert Kovács; Mayela Rodríguez-Violante; Jean-Christophe Corvol; Pille Taba; Klaus Seppi; O. S. Levin; Anette Schrag; Thomas Foltynie; Mario Alvarez-Sanchez; Tomoko Arakaki; Zsuzsanna Aschermann; Iciar Aviles-Olmos; Eve Benchetrit; Charline Benoit; Alberto Bergareche-Yarza; Amin Cervantes-Arriaga; Anabel Chade; Florence Cormier; Veronika Datieva; David A. Gallagher; Nelida Garretto; Zuzana Gdovinova; Oscar Gershanik; Milan Grofik; Vladimir Han; Jing Huang; Liis Kadastik-Eerme; Monica M. Kurtis

The Movement Disorder Society Unified Parkinsons Disease Rating Scale (MDS‐UPDRS) is a newly developed tool to assess Parkinsons disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS‐UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD.


Arquivos De Neuro-psiquiatria | 1994

Síndrome cerebeloso por amiodarona

Nelida Garretto; R. Rey; Guillermo Kohler; Silvia Cocorullo; David A. Monteverde; Blanca I. Ravera; Roberto E.P. Sica

Amidarone (AMD) is an antiarrhythmic drug with side effects on the nervous system. Cerebellum is seldom involved: We describe the case of a 56 years old male patient with a history of 4 month of cerebellar involvement characterized by gait unsteadiness, ataxia, nistagmus and vertigo. He was on treatment with AMD because of ventricular arrythmia. The cerebellar syndrome progressively disappeared after drug withdrawal and he was symptoms-free 4 months later. Similar symptoms appeared after another one month of automedication with the same drug. Structural lesions, metabolic, nutritional deficiencies or toxics were excluded. Mechanisms of cerebellar toxicity of AMD are yet unknown. The knowledge of the toxic effects of this drug, widely used in our country, would allow its early recognition.Amidarone (AMD) is an antiarrhytmic drug with side effects on the nervous system. Cerebellum is seldom involved. We describe the case of a 56 years old male patient with a history of 4 month of cerebellar involvement characterized by gait unstadiness, ataxia, nistagmus and vertigo. He was on treatment with AMD because of ventricular arrythmia. The cerebellar syndrom progressively disappeared after drug whitdrawal and he was symptoms-free 4 months later. Similar symptoms appeared after another one month of automedication with the same drug. Structural lesions, metabolic, nutritional deficiencies or toxics were excluded. Mechanisms of cerebellar toxicity of AMD are yet unknown. The knowledge of the toxic effects of this drug, widely used in our country, would allow its early recognition.

Collaboration


Dive into the Nelida Garretto's collaboration.

Top Co-Authors

Avatar

Tomoko Arakaki

University of Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Mayela Rodríguez-Violante

National Autonomous University of Mexico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pablo Martinez-Martin

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Luz Abaroa

University of Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Jing Huang

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Jose Manuel Rojo-Abuin

Spanish National Research Council

View shared research outputs
Researchain Logo
Decentralizing Knowledge